I. AMENDMENTS TO THE CLAIMS

Please amend the claims as shown in the following listing:

Claim 1 (currently amended): A solid pharmaceutical dosage form comprising a solid particulate dispersion of a pharmaceutical agent in a matrix, the pharmaceutical agent being sparingly water-soluble and comprising crystalline particles dispersed in the matrix to enhance the dissolution rate of the pharmaceutical agent in water, the matrix directly contacting the pharmaceutical agent and consisting of a water-soluble polymer, wherein the solid particulate dispersion is made by mixing the pharmaceutical agent and the polymer at a temperature sufficiently high to melt or soften the polymer, but insufficiently high to melt the pharmaceutical agent so that a matrix coating on the particulate drug substance can be formed, and wherein the solid pharmaceutical dosage form is an orally deliverable form.

Claim 2 (previously presented): The dosage form of Claim 1 wherein the pharmaceutical agent is a glitazone.

Claims 3-4 (canceled)

Claim 5 (previously presented): The dosage form of Claim 1 wherein the polymer is hydroxypropyl cellulose.

Claims 6-9 (canceled)

Claim 10 (previously presented): The dosage form of Claim 1 wherein said dosage form comprises 75 % by weight of said pharmaceutical agent.

Claims 11-20 (canceled)

Claim 21 (currently amended): A solid pharmaceutical dosage form for oral delivery comprising a solid particulate dispersion of a pharmaceutical agent in a matrix, the pharmaceutical agent being sparingly water-soluble and comprising crystalline particles dispersed in the matrix to enhance the dissolution rate of the pharmaceutical

agent in water, the matrix directly contacting the pharmaceutical agent and consisting of at least-one water-soluble polymer, wherein the pharmaceutical agent is a glitazone and the solid particulate dispersion is made by mixing the pharmaceutical agent and the polymer at a temperature sufficiently high to melt or soften the polymer, but insufficiently high to melt the pharmaceutical agent so that a matrix coating on the pharmaceutical agent can be formed.

Claim 22 (previously presented): The dosage form of Claim 21 wherein the polymer is hydroxypropyl cellulose.

Claim 23 (previously presented): The dosage form of Claim 21 wherein the pharmaceutical agent and the polymer are present at a weight ratio of 75:25, respectively.

Claim 24 (previously presented): The dosage form of Claim 1, wherein the pharmaceutical agent comprises about 10 % to about 90 % of the solid particulate dispersion by weight.

Claim 25 (previously presented): The dosage form of Claim 1, wherein the pharmaceutical agent comprises about 20 % to about 80 % of the solid particulate dispersion by weight.

Claim 26 (previously presented): The dosage form of Claim 1, wherein the pharmaceutical agent comprises about 40 % to about 80 % of the solid particulate dispersion by weight.

Claim 27 (previously presented): The dosage form of Claim 1, wherein the pharmaceutical agent comprises about 50 % to about 80 % of the solid particulate dispersion by weight.